Endoscopic Detection of Dysplasia in Crohn 's Disease Patient

Endoscopic Detection of Small Bowel Dysplasia and Cancer in Patients With Jejuna or Ileal Crohn Disease : Prospective Study in a Cohort of High Risk Patients

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01180452

Acronym

DYDJI

Enrollment

107

Registered

2010-08-12

Start date

2010-01-31

Completion date

2014-06-30

Last updated

2015-06-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn Disease Located in Jejunum or Ileum

Keywords

Crohn disease, dysplasia, adenocarcinoma, endoscopy, jejunum, ileum

Brief summary

Patients with Crohn's disease (CD) have an increased risk of small bowel adenocarcinoma (SBA). Long duration of CD is the main risk factor. SB dysplasia has been associated with SBA in 20% of cases, always described in diseased sites. The progression to neoplasia and natural history remains unknown but progression of inflammation to dysplasia and then to adenocarcinoma is suspected. As for surveillance recommendations for colorectal carcinoma in long standing inflammatory colonic disease, endoscopic screening of SB could be proposed in CD patients with risk factors of SBA. No study can be found in literature. The investigators propose a multicenter exploratory open study on prospective cohort of CD patients with high risk of dysplasia or cancer. The goal is evaluate the rate of dysplasia and adenocarcinoma detected by enteroscopy with biopsies in a high risk CD population

Interventions

PROCEDUREenteroscopy

endoscopic enteroscopy to do biopsies on jejunum

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* More than 18-years-old * Crohn disease on jejunum and/or ileum since at least 10 years * Radiography done during last year

Exclusion criteria

* Dysplasia previously detected * Pregnancy

Design outcomes

Primary

Measure	Time frame	Description
Frequency of dysplasia and adenocarcinoma	2 months	dysplasia will be described as high or low level Samples will be analysed by 2 different team of anapathologists

Secondary

Measure	Time frame	Description
Success of endoscopic detection	1-3 Months	the success will be measured by reaching at least one pathologic area during the endoscopic procedure

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026